The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.
about
My approach to the treatment of sclerodermaConnective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trialsPredictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohortMulticentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolThe Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context.Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicineSystemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosisPressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocolHigh-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesValuation of scleroderma and psoriatic arthritis health states by the general public.Combination therapies for systemic sclerosis.Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Are scores on English and French versions of the PHQ-9 comparable? An assessment of differential item functioning.Lidocaine for systemic sclerosis: a double-blind randomized clinical trial.Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patientsEvaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial.Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form.Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosisLower limb muscle strength is associated with functional performance and quality of life in patients with systemic sclerosis.Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.Psychiatric symptoms and quality of life in systemic sclerosis.High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyPatterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisAssessing body image in patients with systemic sclerosis (scleroderma): validation of the adapted Satisfaction with Appearance Scale.Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisDevelopment and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale.A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Improvement of Mouth Functional Disability in Systemic Sclerosis Patients over One Year in a Trial of Fat Transplantation versus Adipose-Derived Stromal Cells.Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease.Outcome Measures for Clinical Trials in Interstitial Lung Diseases.Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma.A standardized core set for systemic sclerosis clinical trials. First step in development of combined response indexLong-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.Fatigue: an overlooked determinant of physical function in scleroderma.Management of Musculoskeletal Involvement in Systemic SclerosisPain-related diseases and sleep disorders.
P2860
Q24618843-31CC2D09-8E01-44ED-BF0C-B56FC119319BQ27024062-9E768BAA-2F64-4DF3-B325-8A3E28E4D79EQ28743863-40A7F5B8-FD77-4235-980E-6AC65580859AQ30490484-FEFC252C-F677-4E81-AF18-B9817C24206BQ30542602-989E3B29-14CA-4D8A-8926-416EEA29DD4CQ33945954-5CB433BA-DFA8-4E38-969B-2973F284D522Q34027197-AEDF6972-337E-41B3-BE83-39A570E664A0Q34109827-DA468530-90E3-4B8E-97EE-2325449D985AQ34152046-9B21B057-D9DB-4583-B5FA-5CE577B2C40AQ34208626-65FF3C9A-E783-4AAE-B5B9-5BC23B9069C6Q34221999-973BA1C6-BD05-4E5E-AE5F-50D4BD3A3E3BQ34309698-D0CCD31C-794E-4336-9DC6-CEEFDE81735BQ34409802-629A9ACE-8676-4554-8602-4976788A1204Q34517510-081388A2-067C-4B19-8206-84F0752CC1A9Q34585544-D3D4BBE9-522F-4C52-A09F-8A3BA5B83563Q35223302-302A16E5-5B5F-4736-9350-1BC3B8ACE278Q35256824-7E8BE534-32B1-412C-88A5-F9B7680DC013Q35491907-18398E8F-583F-4790-852F-F8BF3BE86717Q35591616-79529D7F-0B75-423D-99EA-78F6D428F991Q35781172-EFC0B70A-7EBD-44E6-A8C8-8F88887B0011Q35785365-23743429-8573-41A5-88BF-1521E6B223E9Q35851777-A17DBFAF-AFD9-4BE4-BE98-8863B48F53B5Q35920153-7A47F707-937A-4299-85DD-4741F1EC643BQ35925071-537D970B-9B1D-4CDC-939D-AC2A23C90AA0Q35977294-6E7EB1FC-1628-47DD-9410-8C3F7BC6A0D5Q36076276-9CC67C48-7A39-4905-B715-7AB6D452FC6AQ36145795-4046EFA3-77C0-430B-A7A8-B8AAC4724BC0Q36171822-0376A93C-56F6-4779-9273-2D2C72C1B46FQ36171844-38C26E89-6DF9-440A-82D5-1F01486DF063Q36471247-97D0CE2A-69DE-4437-AE3F-096C65ADB89CQ36530443-FC223CBB-D6D7-49CE-8956-897351684DCCQ36687460-4646AAE8-42CB-43D8-9532-581F1E255108Q36726418-FF95A6D8-7E5F-4667-936B-1EEABBE1EB4EQ36844687-1DD11806-F4A0-4EF7-B581-C74DD7CE6D61Q36869412-16BCC99A-097D-4F45-A630-EDD0E9280132Q36930712-9EFD13B3-7A22-45AB-8781-7404A11E8BCFQ36985736-97AFF770-1A07-42A1-859F-4B2A32B6AA27Q37089576-0D4E366F-3C2E-4AFA-AD2F-60D226E74F35Q37229495-730E4165-61AC-4114-9A8A-465F8C228C99Q37371267-8293DBEE-834A-4DD6-9376-88B0A2774981
P2860
The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
The value of the Health Assess ...... sclerosis patients over time.
@en
The value of the Health Assess ...... sclerosis patients over time.
@nl
type
label
The value of the Health Assess ...... sclerosis patients over time.
@en
The value of the Health Assess ...... sclerosis patients over time.
@nl
prefLabel
The value of the Health Assess ...... sclerosis patients over time.
@en
The value of the Health Assess ...... sclerosis patients over time.
@nl
P356
P1476
The value of the Health Assess ...... sclerosis patients over time.
@en
P2093
Medsger TA Jr
P2860
P304
P356
10.1002/ART.1780401110
P577
1997-11-01T00:00:00Z